The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance

Carcinogenesis

Volumn 33, Issue 11, 2012, Pages 2076-2083

  Kumari, Ratna ^a   Li, Huan ^a   Haudenschild, Dominik R ^a   Fierro, Fernando ^a   Carlson, Cathy S ^b   Overn, Paula ^c   Gupta, Lalita ^a   Gupta, Kavita ^a   Nolta, Jan ^a   Yik, Jasper H N ^a   Di Cesare, Paul E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LEUKEMIA LYMPHOMA RELATED FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; CHONDROSARCOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE LRF; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL FACTOR;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CHONDROSARCOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM GRADING; ONCOGENES; PROGNOSIS; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868625917     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs254     Document Type: Article

References (38)

1. Lee, F.Y. et al. (1999) Chondrosarcoma of bone: an assessment of outcome. J. Bone Joint Surg. Am., 81, 326-338.
2. Bovée, J.V. et al. (2005) Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol., 6, 599-607.
3. Gelderblom, H. et al. (2008) The clinical approach towards chondrosarcoma. Oncologist, 13, 320-329.
4. Mirra, J.M. et al. (1985) A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin. Orthop. Relat. Res., 201, 214-237.
5. SLICED (2007) Skeletal lesions interobserver correlation among expert diagnosticians study group: Reliability of histopathological and radiologic grading of cartilaginous neoplasms in long bones. J. Bone Joint Surg. Am., 89, 2113-2123.
6. Liu, C.J. et al. (2004) Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. J. Biol. Chem., 279, 47081-47091.
7. Costoya, J.A. et al. (2004) Essential role of Plzf in maintenance of spermatogonial stem cells. Nat. Genet., 36, 653-659.
8. He, X. et al. (2005) The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature, 433, 826-833.
9. Maeda, T. (2005) Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature, 433, 278-285.
10. Aggarwal, A. et al. (2010) Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Exp. Mol. Pathol., 89, 140-148.
11. Aggarwal, H. et al. (2011) Expression of leukemia/lymphoma related factor (LRF/Pokemon) in human benign prostate hyperplasia and prostate cancer. Exp. Mol. Pathol., 90, 226-230.
12. Maeda, T. et al. (2009) LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev. Cell, 17, 527-540.
13. Li, H., et al. (2011) Comparative analysis with collagen type II distinguishes cartilage oligomeric matrix protein as a primary TGFbeta-responsive gene. Osteoarthritis Cartilage, 19, 1246-1253.
14. Jagasia, A.A. et al. (1996) Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett., 105, 91-103.
15. Ouyang, P. (1998) An in vitro model to study mesenchymal-epithelial transformation. Biochem. Biophys. Res. Commun., 246, 771-776.
16. Das, C.M. et al. (2007) Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J. Neurooncol., 85, 159-170.
17. Guntur, V.P. et al. (2010) Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res., 30, 3557-3564.
18. Zhao, Y.F. et al. (2011) P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. Biomed. Pharmacother., 65, 151-156.
19. Bramwell, V.H. et al. (2000) Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma, 4, 103-112.
20. Choi, W.I. et al. (2009) Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p53 and Sp1. J. Biol. Chem., 284, 12633-12644.
21. Xiong, Y. et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
22. el-Deiry, W.S. et al. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
23. Agarwal, M.L. et al. (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. U.S.A., 92, 8493-8497.
24. Taylor, W.R. et al. (2001) Regulation of the G2/M transition by p53. Oncogene, 20, 1803-1815.
25. Kyoung Kim, H., et al. (2005) Down-regulation of a forkhead transcription factor, FOXO3a, accelerates cellular senescence in human dermal fibroblasts. J. Gerontol. A Biol. Sci., 60, 4-9.
26. Brown, J.P. et al. (1997) Bypass of senescence after disruption of p21CIP1/ WAF1 gene in normal diploid human fibroblasts. Science, 277, 831-834.
27. McConnell, B.B. et al. (1998) Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr. Biol., 8, 351-354.
28. Vredeveld, L.C. et al. (2010) Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis, 31, 201-207.
29. Zheng, X. et al. (2004) Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res., 64, 1773-1780.
30. Lauwaet, T. et al. (2000) Molecular mechanisms of invasion by cancer cells, leukocytes and microorganisms. Microbes Infect., 2, 923-931.
31. Burger, J.A. et al. (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107, 1761-1767.
32. Moskovits, N. et al. (2006) p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res., 66, 10671-10676.
33. Roger, L. et al. (2006) Control of cell migration: a tumour suppressor function for p53? Biol. Cell, 98, 141-152.
34. Itahana, K. et al. (2001) Regulation of cellular senescence by p53. Eur. J. Biochem., 268, 2784-2791.
35. Rosier, R.N. et al. (1997) P-glycoprotein expression in cartilaginous tumors. J. Surg. Oncol., 65, 95-105.
36. Wyman, J.J. et al. (1999) Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J. Orthop. Res., 17, 935-940.
37. Kim, D.W. et al. (2009) siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol. Cancer, 8, 28.
38. Kim, D.W. et al. (2007) Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J. Orthop. Res., 25, 820-828.